RxDoctor Payments Data

Shiva Prasad Shashidharan, MD

Cardiovascular Disease · Winter Garden, FLNPI 1588911333

Payments from drug & device makers

$7,306in general payments, 2019–2025

Across 346 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$845
  • Amgen$611
  • Preventric Diagnostics, Inc.$540
  • Medtronic$532
  • Abbott$492
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,306 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$99,245
Medicare patients
341
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$98,024
EntrestoSacubitril/Valsartan29$46,654
JardianceEmpagliflozin18$22,610
XareltoRivaroxaban13$15,258
Metoprolol Succinate101$1,791
Atorvastatin Calcium180$1,553
Losartan Potassium95$1,286
Bumetanide21$953
Furosemide124$747
Midodrine Hcl12$622
Amlodipine Besylate85$605
Metoprolol Tartrate73$519
Spironolactone58$506
Rosuvastatin Calcium36$482
Potassium Chloride23$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$470$98,02479 claims
NovartisEntresto$845$46,65429 claims
Boehringer IngelheimJardiance$113$22,61018 claims
Johnson & JohnsonXarelto$1,224$15,25813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →